文摘

背景:Nilutamide是一个新的、特定的合成抗雄激素,发布在一些国家转移性前列腺癌的治疗。八个病人医疗中心大学第戎和所指的附属医院开发可逆肺透明,在服用这种药物时,呼吸道症状。方法:记录8名患者新,否则无法解释的胸部混浊而采取nilutamide综述。在每个病人仔细病原学的搜索是为其他环境或内源性的原因。6个病人接受支气管肺泡灌洗、灌洗液培养。糖皮质激素不给,除非气体交换妥协(2例)。结果:8例患者(男性)有前列腺癌诊断平均10.2个月。与nilutamide都有改善,大幅降低前列腺特异性抗原水平。七收到nilutamide的推荐剂量150毫克/天,和一个收到了两倍多。治疗持续了平均113(范围10 - 225)天,和平均累积剂量为21.8克(3-38)。 The chest radiographs showed bilateral infiltrates, with no consistent topographic predilection. A restrictive lung defect was present in six patients and hypoxia in all (mean arterial oxygen tension (PaO2) 6.6 kPa). Bronchoalveolar lavage showed lymphocytosis in four patients and neutrophilia in two. The outcome was favourable in all patients after they had stopped nilutamide only (five patients), with corticosteroids (two patients) or a simple reduction of nilutamide from 300 to 150 mg/day (one patient). Recovery was associated with improvement of pulmonary function and PaO2. CONCLUSION: Nilutamide is associated with interstitial pneumonitis in about 1% of patients and appears reversible.